AUPH News and Press, Aurinia Pharmaceuticals Inc From 04/28/21

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia’s management team will also host a conference call at 5:00...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded at a new 52-week low today of $11.61. Approximately 3.9 million shares have changed hands today, as compared to an average 30-day volume of 3.2 million shares. Aurinia Pharmaceuticals Inc share prices have moved between a 52-week high of $...

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded today at $11.68, breaking its 52-week low. This new low was reached on approximately average trading volume as 3.9 million shares traded hands, while the average 30-day volume is approximately 3.2 million shares. Over the past ye...

Aurinia Pharmaceuticals (TSX:AUP) (NASDAQ:AUPH) is a biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company has commercially laun...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30...

Aurinia Pharmaceuticals (AUPH) has announced additional efficacy data from two pivotal trials for Lupkynis™ (voclosporin) in lupus nephritis (“LN”).Lupkynis was approved by the FDA in January as a combination therapy with a background immunosuppressive therapy r...

Additional efficacy data from pooled analysis of AURA-LV and AURORA 1 pivotal trials demonstrate potential to improve renal response regardless of disease progression at diagnosis Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today p...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aurinia (NASDAQ: AUPH ) stock is a bet on a clinical-stage biotech firm tackling lupus nephritis with its drug, Lupkynis. Potential investors should note that the company is no longer in the developmental phases. ...

Aurinia saw its first product, Lupkynis, approved and launched in January, and analysts widely expect it to be a blockbuster. Despite completely removing regulatory risk from the picture, shares are essentially unmoved since before approval. With a market cap just under $2 billion...

This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...